http://www.legislation.gov.uk/uksi/2004/1031/schedule/3/part/4/paragraph/3/made
The Medicines for Human Use (Clinical Trials) Regulations 2004
Medical research
Community health clinics
Medicines
King's Printer of Acts of Parliament
2017-06-16
MEDICINES
These Regulations implement Directive 2001/20/EC on the approximation of laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use (“the Directive”).
The Medicines for Human Use (Clinical Trials) Regulations 2004
Sch. 3 Pt. 2
para. 7
The Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019
reg. 24(3)(c)(i)
reg. 1
The Medicines for Human Use (Clinical Trials) Regulations 2004
Sch. 3 Pt. 2
para. 7
The Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019
reg. 24(3)(c)(ii)
reg. 1
The Medicines for Human Use (Clinical Trials) Regulations 2004
Sch. 3 Pt. 2
para. 8(1)
The Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019
reg. 24(3)(d)(i)
reg. 1
The Medicines for Human Use (Clinical Trials) Regulations 2004
Sch. 3 Pt. 2
para. 8(2)
The Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019
reg. 24(3)(d)(ii)(aa)
reg. 1
The Medicines for Human Use (Clinical Trials) Regulations 2004
Sch. 3 Pt. 2
para. 8(2)
The Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019
reg. 24(3)(d)(ii)(bb)
reg. 1
The Medicines for Human Use (Clinical Trials) Regulations 2004
Sch. 3 Pt. 2
para. 8(2)
The Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019
reg. 24(3)(d)(ii)(cc)
reg. 1
The Medicines for Human Use (Clinical Trials) Regulations 2004
Sch. 3 Pt. 2
para. 8(2)(a)
The Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019
reg. 24(3)(d)(ii)(dd)
reg. 1
SCHEDULE 3PARTICULARS AND DOCUMENTS THAT MUST ACCOMPANY AN APPLICATION FOR AN ETHICS COMMITTEE OPINION, A REQUEST FOR AUTHORISATION, A NOTICE OF AMENDMENT AND A NOTIFICATION OF THE CONCLUSION OF A TRIAL
PART 4NOTIFICATION OF CONCLUSION OF A CLINICAL TRIAL
3
The investigational medicinal product tested in the trial.